2021
The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas
Love C, Pillai R, Ondrejka S, Bhagat G, Chadburn A, McKinney M, Koff J, Soliman D, Czader M, Louissaint A, Li S, Ong C, Behdad A, Evens A, Natkunam Y, Norgaard P, Leppa S, Tse E, Chapman J, Amador C, Fedoriw Y, Bogusz A, Evans A, Goswami R, Juskevicius R, Xu M, Naresh K, Xiong B, Snowden A, Thurman A, Smith E, Dave T, Kositsky R, Thakkar D, Russell V, Roth C, Dave S. The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas. Blood 2021, 138: 2213. DOI: 10.1182/blood-2021-151346.Peer-Reviewed Original ResearchB-cell lymphomaBlood cancersCell lymphomaSpeakers bureauSystematic genomic approachTherapeutic possibilitiesPrimary mediastinal B-cell lymphomaGenomic approachesLarge B-cell lymphomaCentralized pathology reviewMediastinal B-cell lymphomaCancer Genome ProjectTherapeutic developmentMature B-cell lymphomasDetailed clinical informationClinical data reviewPlasma cell myelomaMolecular featuresWhole-exome sequencingRNA sequencingGenome ProjectMETHODS/RESULTSFoundation MedicinePathologic factorsPathology review
2019
Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing
Ma J, Nie K, Inghirami G, Eng K, Elemento O, Au-Yeung R, Shen Y, Srivastava G, Gong J, Xu M, Tan L, Tam W. Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing. Blood 2019, 134: 2770. DOI: 10.1182/blood-2019-125448.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaRelapsed diffuse large B-cell lymphomaWhole-exome sequencingPre-treatment tumorsVariant allele frequencyPre-treatment samplesAxonal guidance signalingRelapse samplesR-CHOPNormal controlsDLBCL cohortProgression-free survival ratesReceptor signalingExome sequencingLarge B-cell lymphomaFree survival rateFront-line treatmentILK signalingThird of patientsAryl hydrocarbon receptor signalingNovel therapeutic approachesB-cell lymphomaGuidance signalingNovel pathogenic pathwaysInstitutional review board